Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Recruiting · NCT07339254 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Non-Interventional Study
What this trial is about
This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \* Age ≥ 18 years.
- \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
- \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
- \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.
Exclusion criteria
- \* Patients is unable to consent for themselves
- \* Patient has not yet completed the 1st cycle of ICI-based therapy
Where it is running
2 locations listed across 1 US state.
- Los Angeles General Medical Center - Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center - Los Angeles, California, United States